Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Oct;37(8):619-28.
doi: 10.1097/DBP.0000000000000334.

A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome

Laura Greiss Hess  1 , Sarah E Fitzpatrick, Danh V Nguyen, Yanjun Chen, Kimberly N Gaul, Andrea Schneider, Kerrie Lemons Chitwood, Marwa Abd Al Azaim Eldeeb, Jonathan Polussa, David Hessl, Susan Rivera, Randi J Hagerman
Affiliations
Randomized Controlled Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome

Laura Greiss Hess et al. J Dev Behav Pediatr. 2016 Oct.

Abstract

Objective: Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS).

Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years.

Results: Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale-Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred.

Conclusion: This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure-Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consolidated Standards of Reporting Trials (CONSORT) flow diagram of subject disposition.
Figure 2
Figure 2
Effect sizes and 95% confidence intervals (CIs) for exploratory secondary measures for the Mullen Early Scales of Learning (MSEL). Given effect size are post treatment score difference estimates (sertraline minus placebo) adjusted for baseline measure, along with 95% CIs (arrows indicate CI length truncated for display). Asterisks indicate P < 0.05.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Santoro MR, Bray SM, Warren ST. Molecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective. Annual Review of Pathology: Mechanisms of Disease. 2012;7(1):219–245. - PubMed
    1. Tejada MI, Glover G, Martínez F, et al. Molecular testing for fragile X: Analysis of 5062 tests from 1105 fragile X families - Performed in 12 clinical laboratories in Spain. BioMed Research International. 2014:2014. - PMC - PubMed
    1. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–914. - PubMed
    1. Tassone F, Iong KP, Tong T-H, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100. - PMC - PubMed
    1. Abbeduto L, Brady N, Kover ST. Language development and fragile X syndrome: Profiles, syndrome-specificity, and within-syndrome differences. Mental Retardation and Developmental Disabilities Research Reviews. 2007;13(1):36–46. - PMC - PubMed

Publication types

MeSH terms